Eucrates Biomedical Acquisition - Units (1 Ord & 1/3 War) Operating Income

As of the most recent data (December 2022), EUCRU shows a operating income of $-700K. That compares with $-1M in the prior-year period — up 30.3% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, EUCRU's operating income is now $-700K (was $-1M) — a 30.3% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Eucrates Biomedical Acquisition - Units (1 Ord & 1/3 War) is outperforming or lagging.

Tracking EUCRU's operating income over time shows whether Eucrates Biomedical Acquisition - Units (1 Ord & 1/3 War) is scaling, shrinking, or reshaping that part of the business. The current reading is $-700K That compares with $-1M in the prior-year period — up 30.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this operating income page, Stockcircle has Eucrates Biomedical Acquisition - Units (1 Ord & 1/3 War)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect operating income (currently $-700K) with ownership activity and broader fundamentals.